MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma

BACKGROUND: Phosphorylated peptides presented by MHC molecules represent a new class of neoantigens expressed on cancer cells and recognized by CD8 T-cells. These peptides are promising targets for cancer immunotherapy. Previous work identified an HLA-A*0201-restricted phosphopeptide from insulin re...

Descripción completa

Detalles Bibliográficos
Autores principales: Engelhard, Victor H, Obeng, Rebecca C, Cummings, Kara L, Petroni, Gina R, Ambakhutwala, Angela L, Chianese-Bullock, Kimberly A, Smith, Kelly T, Lulu, Amanda, Varhegyi, Nikole, Smolkin, Mark E, Myers, Paisley, Mahoney, Keira E, Shabanowitz, Jeffrey, Buettner, Nico, Hall, Emily H, Haden, Kathleen, Cobbold, Mark, Hunt, Donald F, Weiss, Geoffrey, Gaughan, Elizabeth, Slingluff, Jr, Craig L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228659/
https://www.ncbi.nlm.nih.gov/pubmed/32385144
http://dx.doi.org/10.1136/jitc-2019-000262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228659/
https://www.ncbi.nlm.nih.gov/pubmed/32385144
http://dx.doi.org/10.1136/jitc-2019-000262

Ejemplares similares